208 related articles for article (PubMed ID: 34464081)
1. Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy.
Jiang L; Gu Y; Du Y; Tang X; Wu X; Liu J
ACS Appl Mater Interfaces; 2021 Sep; 13(36):42411-42428. PubMed ID: 34464081
[TBL] [Abstract][Full Text] [Related]
2. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis.
Shi J; Ren Y; Ma J; Luo X; Li J; Wu Y; Gu H; Fu C; Cao Z; Zhang J
J Nanobiotechnology; 2021 Jun; 19(1):188. PubMed ID: 34162396
[TBL] [Abstract][Full Text] [Related]
3. αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma.
Gu Y; Du Y; Jiang L; Tang X; Li A; Zhao Y; Lang Y; Liu X; Liu J
J Nanobiotechnology; 2022 Aug; 20(1):384. PubMed ID: 35999612
[TBL] [Abstract][Full Text] [Related]
4. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Triptolide-Loaded Exosomes on the Proliferation and Apoptosis of Human Ovarian Cancer SKOV3 Cells.
Liu H; Shen M; Zhao D; Ru D; Duan Y; Ding C; Li H
Biomed Res Int; 2019; 2019():2595801. PubMed ID: 31240207
[TBL] [Abstract][Full Text] [Related]
6. Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1.
Dai H; Jiang Y; Luo Y; Bie P; Chen Z
Phytomedicine; 2019 Sep; 62():152953. PubMed ID: 31128486
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer.
Wang Y; Liu T; Li H
J Biomater Sci Polym Ed; 2016; 27(7):545-56. PubMed ID: 26786618
[TBL] [Abstract][Full Text] [Related]
8. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
9. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.
Zheng Y; Kong F; Liu S; Liu X; Pei D; Miao X
Drug Deliv; 2021 Dec; 28(1):2033-2043. PubMed ID: 34569906
[TBL] [Abstract][Full Text] [Related]
10. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
11. Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.
Liu Y; Xiao E; Yuan L; Li G
DNA Cell Biol; 2014 Jul; 33(7):418-25. PubMed ID: 24720675
[TBL] [Abstract][Full Text] [Related]
12. Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells.
Hung FM; Chen YL; Huang AC; Hsiao YP; Yang JS; Chung MT; Chueh FS; Lu HF; Chung JG
Oncol Rep; 2013 Mar; 29(3):1053-60. PubMed ID: 23314229
[TBL] [Abstract][Full Text] [Related]
13. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.
Yang M; Gu Y; Yang D; Tang X; Liu J
J Nanobiotechnology; 2017 Dec; 15(1):88. PubMed ID: 29202753
[TBL] [Abstract][Full Text] [Related]
14. Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model.
Shamili FH; Bayegi HR; Salmasi Z; Sadri K; Mahmoudi M; Kalantari M; Ramezani M; Abnous K
Int J Pharm; 2018 Oct; 549(1-2):218-229. PubMed ID: 30075248
[TBL] [Abstract][Full Text] [Related]
15. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ.
Cai J; Yi M; Tan Y; Li X; Li G; Zeng Z; Xiong W; Xiang B
J Exp Clin Cancer Res; 2021 Jun; 40(1):190. PubMed ID: 34108030
[TBL] [Abstract][Full Text] [Related]
16. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.
Zheng S; Wang J; Ding N; Chen W; Chen H; Xue M; Chen F; Ni J; Wang Z; Lin Z; Jiang H; Liu X; Wang L
J Nanobiotechnology; 2021 Nov; 19(1):381. PubMed ID: 34802453
[TBL] [Abstract][Full Text] [Related]
17. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
Lin Y; Yang X; Lu M; Zheng W; Zhang J; Zhuang H; Hua ZC
Anticancer Drugs; 2013 Oct; 24(9):945-57. PubMed ID: 23958791
[TBL] [Abstract][Full Text] [Related]
18. Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer.
He J; Peng T; Peng Y; Ai L; Deng Z; Wang XQ; Tan W
J Am Chem Soc; 2020 Feb; 142(6):2699-2703. PubMed ID: 31910009
[TBL] [Abstract][Full Text] [Related]
19. LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo.
Xu H; Fan X; Zhang G; Liu X; Li Z; Li Y; Jiang B
Biomed Pharmacother; 2017 Sep; 93():1004-1009. PubMed ID: 28724258
[TBL] [Abstract][Full Text] [Related]
20. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
